Sobi announced that the European Commission has approved Aspaveli® (pegcetacoplan) to treat adults with paroxysmal nocturnal haemoglobinuria and haemolytic anaemia.

Lenvatinib, marketed under the brand name Lenvima, is a multikinase inhibitor specifically targeting vascular endothelial growth factor (VEGF) receptors.

Phanes Therapeutics, Inc. has entered into a clinical supply deal with Roche to test PT217 alongside an anti-PD-L1 treatment.

Adjuvants are substances used in vaccines to enhance the body's immune response to an antigen.

Neurocrine Biosciences, Inc. has launched its Phase 1 clinical trial, marking the first time humans are being evaluated.

Tirofiban, marketed under the brand name Aggrastat, is a potent medication that belongs to the class of glycoprotein IIb/IIIa receptor inhibitors.

The disclosed CS5001 is an ADC targeting ROR1, featuring a unique design.

Adjuvants are substances that are added to vaccines to enhance the body's immune response to an antigen (a substance that can trigger an immune response).

Biotheryx, Inc. revealed that their Investigational New Drug application for BTX-9341, an innovative bifunctional degrader targeting cyclin-dependent kinase 4/6 (CDK4/6).

Axicabtagene ciloleucel, branded as Yescarta, is a revolutionary immunotherapy medication developed by Kite Pharma, a subsidiary of Gilead Sciences.

CMG901 (AZD0901) is a potentially first-in-class antibody-drug conjugate targeting Claudin 18.2, conjugated with monomethyl auristatin E (MMAE) as the payload.

A dose escalation trial, also known as a dose-ranging study, is a type of clinical trial design used primarily in Phase I of drug development.